<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28651642</article-id><article-id pub-id-type="pmc">5485510</article-id><article-id pub-id-type="publisher-id">1838</article-id><article-id pub-id-type="doi">10.1186/s12906-017-1838-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A pilot randomized controlled trial of acupuncture at the <italic>Si Guan Xue</italic> for cancer pain</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lam</surname><given-names>To-Yi</given-names></name><address><email>lty391@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Li-Ming</given-names></name><address><email>lulimingleon@126.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ling</surname><given-names>Wai-Man</given-names></name><address><email>lingwm1@ha.org.hk</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lin</surname><given-names>Li-Zhu</given-names></name><address><phone>+86 13501505588</phone><email>lizhulin903@139.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8848 7685</institution-id><institution-id institution-id-type="GRID">grid.411866.c</institution-id><institution>Department of Oncology, </institution><institution>Guangzhou University of Chinese Medicine, </institution></institution-wrap>Guangzhou, 510405 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.413402.0</institution-id><institution/><institution>The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, </institution></institution-wrap>Guangzhou, 510120 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1771 4093</institution-id><institution-id institution-id-type="GRID">grid.417134.4</institution-id><institution/><institution>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, </institution></institution-wrap>3 Lok Man Road, Chai Wan, Hong Kong </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>335</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><title>Abstracts</title><sec><title>Background</title><p id="Par1">Pain is a common symptom in cancer patients. Acupuncture is a suggested treatment for a wide range of clinical conditions, usually for its beneficial effects on pain control. <italic>Si guan xue</italic> (the four points) have been widely used in clinical practice, and has shown that it is highly effective, effective in obtaining <italic>qi</italic>, shows strong acupuncture stimulation, and is simple to manipulate and safe to use. Therefore, the aim of this study is to test the protocol and safety of acupuncture at the <italic>si guan xue</italic> in the management of cancer pain.</p></sec><sec><title>Methods</title><p id="Par2">This is a single-blind, randomized controlled pilot trial. 42 patients with moderate to severe cancer pain were randomly assigned to three different arms with seven sessions of treatment; that is, treatment arm 1 (the <italic>si guan xue</italic> arm, <italic>n</italic>&#x000a0;=&#x000a0;14), treatment arm 2 (the <italic>si guan xue</italic> plus commonly used acupoints arm, <italic>n</italic>&#x000a0;=&#x000a0;14) and the control arm (the commonly used acupoints arm <italic>n</italic>&#x000a0;=&#x000a0;14). Primary outcomes included acupuncture relieving cancer pain, and patients&#x02019; subjective improvement as measured by the Patient Global Impression of Change (PGIC). Secondary outcomes included the scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Karnofsky&#x02019;s Performance Status (KPS).</p></sec><sec><title>Results</title><p id="Par3">The analysis showed that the cancer pain reduction in treatment arm 2 was most prominent on day 5 when compared with the control arm (<italic>P</italic>&#x0003c;0.05). There was no difference in the scores of PGIC, EORTC QLQ-C30 or KPS among the three groups (<italic>P</italic>&#x0003e;0.05). Furthermore, no serious adverse events were observed.</p></sec><sec><title>Conclusions</title><p id="Par4">These results indicate that acupuncture at the <italic>si guan xue</italic> plus commonly used acupoints tends to be effective in reducing cancer pain. However, the sample size was small, and a future multi-centre study with a larger sample size is warranted.</p></sec><sec><title>Trial registration</title><p id="Par5">
<ext-link ext-link-type="uri" xlink:href="http://www.medresman.org/">ChiCTR-IOR-15007471</ext-link> (Retroactively registered on 28 NOV 2015)</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Acupuncture</kwd><kwd><italic>Si guan Xue</italic></kwd><kwd>Cancer pain</kwd><kwd>Randomized controlled trial</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par13">Cancer is one of the world&#x02019;s leading causes of death. According to recent reports, 12.7 million people diagnosed with cancer in 2008, and 7.6 million people died of it, accounting for 13% of all the deaths. It has been predicted that the total number of cancer deaths worldwide will increase from 13% in 2007 to 45% in 2030. For newly developed countries, the number is expected to increase from 11.3 million in 2007 to 15.5 million in 2030 [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par14">Pain is a common cancer symptom. According to the World Health Organization (WHO) in 1995, there are 24.6 million cancer patients worldwide, 20% to 30% of whom suffer from various levels of pain. Although the three-step analgesic ladder of the WHO has been widely used, there is still a paucity of effective pain controls for many cancer patients, especially those in advanced stages of the disease. Many of these patients need to use analgesics such as opioids which act on the central nervous system. However, they may cause serious side effects, including nausea, vomiting, constipation, dryness of mouth, urinary retention, sleep disturbance, confusion, hallucinations, or even respiratory distress. They can give rise to intolerance among patients and coping difficulty for their families [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par15">Acupuncture is recommended for a wide range of clinical conditions. In particular, it has beneficial effects on pain control, and more importantly is safe to use. The benefits of acupuncture include rapid onset of analgesic effect, long sustained remission, ease of application, no risk of drug dependence or addiction, and by and large the absence of serious side effects [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par16">
<italic>Si guan xue</italic> is a unique combination of acupoints for acupuncture. It was first described in the "Twelve of the original nine-pin, <italic>Lingshu.</italic>" It pointed out that "there are five <italic>zang</italic> and six <italic>fu</italic>. The six <italic>fu</italic> come from twelve original <italic>fu</italic>. The original twelve come from the <italic>si</italic> (four) <italic>guan</italic>. The <italic>si guan</italic> treat the five <italic>zang.</italic>" Then Yang Jizhou, a famous Chinese Medicine Practitioner of the Ming Dynasty added that, "the <italic>si guan</italic> are <italic>Taichong</italic> (LR3) and <italic>Hegu</italic> (LI4)" [<xref ref-type="bibr" rid="CR5">5</xref>]. The combination of these acupoints has the important effect of communicating the <italic>yin</italic> and <italic>yang</italic>, <italic>zang</italic> and <italic>fu</italic>, superior and inferior parts of the human body, and the <italic>qi</italic> and blood, and thus complementing each other. The <italic>si guan xue</italic> are widely used clinically. They have high treatment efficacy, easily get to the <italic>qi</italic>, are simple to manipulate, and safe to use [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Their clinical use and efficacy for many clinical conditions are worthy of further studies. Therefore, this pilot study aims at testing the safety of acupuncture at the <italic>si guan xue</italic> in the management of cancer pain and informing the protocol for a larger study.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Settings and subjects</title><p id="Par17">A pilot randomized clinical trial was conducted in the Department of Oncology at the First Affiliated Hospital of Guangzhou University of Chinese Medicine and at the OncWell Integrated Cancer Centre in Hong Kong. The trial lasted from May 2012 to February 2014. The study protocol was approved by the Ethics Committee of Hong Kong East Cluster (Reference no.: HKEC-2012-024) before the start of the study. The reporting of the study complied with the requirements of the CONSORT 2010 statement [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par18">Patients who fulfilled the following criteria were recruited into this study: (1) having advanced cancer with cancer pain as the chief complaint; (2) no chemotherapy or radiotherapy within one month before the study; (3) men or women aged 18&#x000a0;years or above; (4) levels of conscious to the extent that he/she could evaluate and report on their pain; (5) life expectancy of three months or above; and (6) capability of giving informed consent. Those with the following conditions were excluded: (1) pain was unrelated to cancer; (2) inability to report his/her pain accurately; (3) mental illness or lack capacity; (4) children or pregnant/lactating women; (5) other serious diseases; (6) unwillingness to cooperate or give informed consent [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec4"><title>Randomization and blinding</title><p id="Par19">A computer program was used to randomize the participants [<xref ref-type="bibr" rid="CR14">14</xref>]. The study coordinator was responsible for allocating the randomization codes that indicated the arms into the sequentially numbered and sealed envelopes. These envelopes were concealed from the investigators. In this pilot study, neither the investigators nor the participants were blinded, however the analyst was blinded.</p></sec><sec id="Sec5"><title>Treatment procedures</title><p id="Par20">The Chinese Medicine style of acupuncture was used. Acupuncture was conducted by two qualified Chinese Medicine Practitioners with nine and twelve years of experience in clinical practice, and three and ten years of acupuncture experience respectively. Both have bachelor&#x02019;s and master&#x02019;s degrees in Chinese Medicine related fields (one of whose master&#x02019;s degrees is in acupuncture), and are well trained in acupuncture. A course of acupuncture with seven treatment sessions, delivered either daily or on alternating days, was given to the patients in the three arms. The standards of the study complied with the requirements of the Checklist for items in the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) 2010 [<xref ref-type="bibr" rid="CR15">15</xref>].</p><sec id="Sec6"><title>Theoretical basis for using acupuncture to treat cancer pain</title><p id="Par21">The design of our acupuncture treatment protocol was based on traditional Chinese Medicine theory. Pathophysiology of cancer pain, based on Western Medicine, did not affect the formulation of acupuncture interventions in this study. According to the Chinese medical diagnosis, diseases can be conceptualized as conditions of deficiency or strength. The former refers to the insufficiency of <italic>qi</italic> and blood, <italic>ying</italic> and <italic>yang</italic>, <italic>zang fu</italic> etc., whereas the latter implies a surplus of <italic>qi</italic> and blood. The normal circulation of <italic>qi</italic> and blood in the meridians requires warming by <italic>yang</italic>, moisturizing by <italic>yin</italic>, promotion by <italic>qi</italic> and the nourishment by blood. Deficiency of these elements leads to the malnutrition of <italic>zang fu,</italic> and then the pain. Deficiency is more prominent in advanced cancer patients [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The <italic>si guan xue</italic> have been considered to have an important effect on communicating the <italic>yin</italic> and <italic>yang</italic>, <italic>zang</italic> and <italic>fu</italic>, superior and inferior parts of the human body, as well as the <italic>qi</italic> and blood. They thus complement each other. Hence, we hypothesized that <italic>si guan xue</italic> would enhance the treatment effects of the commonly used acupoints.</p></sec><sec id="Sec7"><title>The choice of Acupoints</title><p id="Par22">There were two treatment arms in the study. Treatment arm 1 used only the <italic>si guan xue</italic>, whereas treatment arm 2 used the <italic>si guan xue</italic> in combination with a set of commonly used acupoints. This set of commonly used acupoints, including <italic>Neiguan</italic> (PC6), <italic>Zusanli</italic> (ST36) and <italic>Sanyinjiao</italic> (SP6), were chosen according to a previous extensive literature review [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. They also constituted the control arm of the pilot study. All these acupoints, especially those located below the elbow and knee joints of the twelve regular meridians, have therapeutic effects on diseases in both the local and the remote regions.</p></sec><sec id="Sec8"><title>Acupuncture intervention</title><p id="Par23">Single-use acupuncture needles (0.25 x 25 mm or 0.30 x 40 mm) manufactured by MOCM International Development Limited were inserted under the skin at 10-20&#x000a0;mm vertical depth. Then, a reinforcing-reducing method was used to activate the <italic>qi</italic> until the sensation of the arrival of <italic>qi</italic> (numbness, fullness and heaviness) was reported by patients. Patients were maintained in supine positions with the needles left in situ for 30&#x000a0;min. A course of acupuncture treatment consisted of seven sessions in total, performed either daily or on alternating days. Safety precautions were conducted for the patients before each treatment session to prevent acupuncture related adverse events such as fainting, hematoma, curved needles and broken needles.</p></sec></sec><sec id="Sec9"><title>Clinical assessment</title><p id="Par24">The primary outcome of the study, the change in pain, was evaluated by two methods. Firstly, it was measured by the pain assessment form with a numeric rating scale (NRS) from 0 to 10 (0&#x000a0;=&#x000a0;the best, 10&#x000a0;=&#x000a0;the worst) [<xref ref-type="bibr" rid="CR33">33</xref>]. Secondly, patients&#x02019; subjective improvement was assessed using the Patient Global Impression of Change (PGIC) [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par25">Secondary outcomes included the scores determined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [<xref ref-type="bibr" rid="CR35">35</xref>] and the Karnofsky&#x02019;s Performance Status (KPS). Three sets of EORTC QLQ-C30 were completed by the participants; that is, before the start of the study, after completing the 7th acupuncture treatment, and during the follow-up visit 2&#x000a0;weeks after the treatment. KPS was assessed on each follow-up visit.</p></sec><sec id="Sec10"><title>Statistical analysis</title><p id="Par26">The analyses were performed on the intention-to-treat population, defined as the participants who had completed baseline assessment and at least one evaluation after treatment. A repeated measures design approach was adopted to compare the treatment outcomes (the score of cancer pain reduction, Global Health Scale, Functional Scale, Symptom Scale and KPS) over time between the three groups. A model was established for performing longitudinal data analysis to explore the intervention effect and the time effect. Among-group differences at each measure time point were further examined using Analysis of Variance (ANOVA). Categorical variables, including categorical baseline variables and incidence of adverse events, were analyzed using a Chi-square (<italic>&#x003c7;</italic>
<sup><italic>2</italic></sup>) or Fisher Exact test. Statistical significance was defined as a two-tailed <italic>P&#x000a0;&#x0003c;</italic>&#x000a0;0.05. Statistical analysis was performed by SPSS 20.0 (IBM SPSS Inc., Armonk, New York, USA) and SAS 9.2 software (SAS Institute Inc., Cary, USA).</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Baseline characteristics</title><p id="Par27">
<list list-type="order"><list-item><p id="Par28">General Information on the Accrued Patients</p></list-item></list>
</p><p id="Par29">From May 2012 to February 2014, 45 cancer patients were screened. 3 refused to participate in this study because of geographical reasons or unwillingness to accept acupuncture. 42 participants (30 on the Mainland and 12 in Hong Kong) were randomly assigned to the three study arms with 14 in each of them (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). 30 (71.4%) participants completed planned course of treatment. However, since all participants finished at least 2 sessions of treatment and at least 2 evaluations after treatment, they were all included in the data analysis.<fig id="Fig1"><label>Fig. 1</label><caption><p>Research Flowchart</p></caption><graphic xlink:href="12906_2017_1838_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par30">Baseline characteristics of the patients are listed in Table <xref rid="Tab1" ref-type="table">1</xref>. There were 20 men and 22 women. For patients on the Mainland, the majority had their primary cancer disease in the lung (<italic>n</italic>&#x000a0;=&#x000a0;11), while it was in the head or neck for those in Hong Kong (<italic>n</italic>&#x000a0;=&#x000a0;4). Most of the patients had stage IV cancer (<italic>n</italic>&#x000a0;=&#x000a0;37), and some had been suffering from another chronic disease as well (<italic>n</italic>&#x000a0;=&#x000a0;26) (Table <xref rid="Tab1" ref-type="table">1</xref>). Before the acupuncture, the mean of pain score was 5.81, which was a moderate level of pain [<xref ref-type="bibr" rid="CR33">33</xref>]. KPS was 70%, indicating that they could have lived independently, but could not have maintained normal activities or work [<xref ref-type="bibr" rid="CR36">36</xref>]. Moreover, the use of analgesics was recorded for all accrued patients. There was no statistically significant difference in analgesic use among the three study arms (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05) (Tables <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of patients (<italic>n</italic>&#x000a0;=&#x000a0;45)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>General Information</th><th>All patients</th><th colspan="2">Participants</th><th>Unwilling participants</th></tr><tr><th/><th/><th>Mainland China</th><th>Hong Kong</th><th>Hong Kong</th></tr></thead><tbody><tr><td colspan="5">Sex</td></tr><tr><td>&#x02003;Male</td><td>20 (47.62)</td><td>15 (50)</td><td>5 (41.67)</td><td>0 (0)</td></tr><tr><td>&#x02003;Female</td><td>22 (52.38)</td><td>15 (50)</td><td>7 (58.33)</td><td>3 (100)</td></tr><tr><td colspan="5">Age</td></tr><tr><td>&#x02003;Average</td><td>57.59</td><td>56</td><td>59.17</td><td>78.33</td></tr><tr><td>&#x02003;Range</td><td>24&#x02013;91</td><td>24&#x02013;79</td><td>42&#x02013;91</td><td>74&#x02013;82</td></tr><tr><td colspan="5">Marital status</td></tr><tr><td>&#x02003;Single</td><td>2 (4.76)</td><td>0 (0)</td><td>2 (16.67)</td><td>0 (0)</td></tr><tr><td>&#x02003;Married</td><td>38 (90.48)</td><td>30 (100)</td><td>8 (66.66)</td><td>2 (67)</td></tr><tr><td>&#x02003;Widowed</td><td>2 (4.76)</td><td>0 (0)</td><td>2 (16.67)</td><td>1 (33)</td></tr><tr><td colspan="5">Education</td></tr><tr><td>&#x02003;Illiteracy</td><td>8 (19.05)</td><td>6 (20)</td><td>2 (16.67)</td><td>1 (33)</td></tr><tr><td>&#x02003;Primary school</td><td>13 (30.95)</td><td>12 (30)</td><td>1 (8.33)</td><td>1 (33)</td></tr><tr><td>&#x02003;Secondary school</td><td>2 (4.76)</td><td>2 (6.67)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>&#x02003;High school</td><td>14 (33.33)</td><td>9 (30)</td><td>5 (41.67)</td><td>1 (33)</td></tr><tr><td>&#x02003;University or above</td><td>5 (11.91)</td><td>1 (3.33)</td><td>4 (33.33)</td><td>0 (0)</td></tr><tr><td colspan="5">Primary Disease Site</td></tr><tr><td>&#x02003;Head and neck</td><td>5 (11.9)</td><td>1 (3.33)</td><td>4 (33.33)</td><td>1 (33)</td></tr><tr><td>&#x02003;Lung</td><td>12 (28.57)</td><td>11 (36.67)</td><td>1 (8.33)</td><td>1 (33)</td></tr><tr><td>&#x02003;Breast</td><td>3 (7.14)</td><td>1 (3.33)</td><td>2 (16.67)</td><td>0 (0)</td></tr><tr><td>&#x02003;Gynecological</td><td>6 (14.29)</td><td>5 (16.67)</td><td>1 (8.33)</td><td>0 (0)</td></tr><tr><td>&#x02003;Liver</td><td>5 (11.9)</td><td>5 (16.67)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>&#x02003;Upper GI (Esophagus, stomach and spleen)</td><td>5 (11.9)</td><td>3 (10)</td><td>2 (16.67)</td><td>0 (0)</td></tr><tr><td>&#x02003;Lower GI(Colon)</td><td>3 (7.14)</td><td>2 (6.67)</td><td>1 (8.33)</td><td>0 (0)</td></tr><tr><td>&#x02003;Other</td><td>3 (7.14)</td><td>2 (6.67)</td><td>1 (8.33)</td><td>1 (33)</td></tr><tr><td colspan="5">Stage of cancer</td></tr><tr><td>&#x02003;III</td><td>5 (11.9)</td><td>1 (3.33)</td><td>4 (33.33)</td><td>0 (0)</td></tr><tr><td>&#x02003;IV</td><td>37 (88.1)</td><td>29 (96.67)</td><td>8 (66.67)</td><td>3 (100)</td></tr><tr><td>Other chronic diseases</td><td>26 (61.9)</td><td>20 (66.67)</td><td>6 (50)</td><td>2 (67)</td></tr><tr><td colspan="5">Level of pain</td></tr><tr><td>&#x02003;Average</td><td>5.81</td><td>5.9</td><td>5.58</td><td>7</td></tr><tr><td>&#x02003;Range</td><td>2&#x02013;8</td><td>2&#x02013;8</td><td>5&#x02013;8</td><td>5&#x02013;8</td></tr><tr><td colspan="5">KPS score</td></tr><tr><td>&#x02003;Average</td><td>70</td><td>69</td><td>72.5</td><td>70</td></tr><tr><td>&#x02003;Range</td><td>40&#x02013;90</td><td>40&#x02013;90</td><td>60&#x02013;80</td><td>60&#x02013;80</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Use of analgesics in the three study arms</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Use or not</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Yes</td><td>10</td><td>6</td><td>7</td><td char="." align="char">0.287</td></tr><tr><td>No</td><td>4</td><td>8</td><td>7</td><td/></tr></tbody></table></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Types of analgesics used in the three study arms</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drugs</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th></tr></thead><tbody><tr><td>Morphine</td><td>0</td><td>3</td><td>2</td></tr><tr><td>Oxycodone</td><td>3</td><td>1</td><td>3</td></tr><tr><td>Fentanyl patch</td><td>3</td><td>3</td><td>4</td></tr><tr><td>Celecoxib</td><td>2</td><td>1</td><td>1</td></tr><tr><td>Tramadol</td><td>2</td><td>0</td><td>0</td></tr><tr><td>Carbamazepine</td><td>0</td><td>2</td><td>1</td></tr><tr><td>Meloxicam</td><td>0</td><td>1</td><td>0</td></tr></tbody></table><table-wrap-foot><p>Note:<italic> P</italic> = 0.513</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec13"><title>Information on pain patients before treatment</title><p id="Par32">The number of pain sites for each participant ranged from 1 to 7. There were 90 pain sites in total. Most were located on the lower limbs (<italic>n</italic>&#x000a0;=&#x000a0;20) (Table <xref rid="Tab4" ref-type="table">4</xref>). The average NRS pain score over the previous 24&#x000a0;h before acupuncture was 5.62. Nonetheless, the average NRS score for the most severe pain was as high as 7.48, which was defined as &#x0201c;severe&#x0201d; according to the NRS. The occurrence of this severe NRS pain score was 4.74 on average. The average for even the slightest NRS pain score was 3.1 (Table <xref rid="Tab5" ref-type="table">5</xref>). The average NRS pain score right before acupuncture was 5.8, a moderate level of pain [<xref ref-type="bibr" rid="CR33">33</xref>].<table-wrap id="Tab4"><label>Table 4</label><caption><p>Distribution of pain sites</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Pain sites</th><th colspan="3">Number of sites</th></tr><tr><th>All</th><th>Mainland China</th><th>Hong Kong</th></tr></thead><tbody><tr><td>Head</td><td>2</td><td>0</td><td>2</td></tr><tr><td>Neck and shoulder</td><td>10</td><td>2</td><td>8</td></tr><tr><td>Upper limb</td><td>8</td><td>1</td><td>7</td></tr><tr><td>Upper back</td><td>12</td><td>8</td><td>4</td></tr><tr><td>Lower back</td><td>10</td><td>8</td><td>2</td></tr><tr><td>Chest</td><td>8</td><td>5</td><td>3</td></tr><tr><td>Upper abdomen</td><td>7</td><td>5</td><td>2</td></tr><tr><td>Lower abdomen</td><td>8</td><td>5</td><td>3</td></tr><tr><td>Lower limb</td><td>20</td><td>11</td><td>9</td></tr><tr><td>Other</td><td>5</td><td>2</td><td>3</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab5"><label>Table 5</label><caption><p>NRS on the level of pain over the previous 24&#x000a0;h</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Level of pain</th><th>All patients</th><th>Mainland China</th><th>Hong Kong</th></tr></thead><tbody><tr><td>Average of most severe pain</td><td>7.48</td><td>7.87</td><td>6.5</td></tr><tr><td>&#x02003;Range</td><td>3&#x02013;10</td><td>5&#x02013;10</td><td>3&#x02013;9</td></tr><tr><td>Average number of severe pain outbursts</td><td>4.74</td><td>4.3</td><td>5.83</td></tr><tr><td>&#x02003;Range</td><td>0&#x02013;9</td><td>1&#x02013;8</td><td>0&#x02013;9</td></tr><tr><td>Average range of slightest pain</td><td>3.1</td><td>2.93</td><td>3.5</td></tr><tr><td>&#x02003;Range</td><td>0&#x02013;8</td><td>0&#x02013;7</td><td>0&#x02013;8</td></tr><tr><td>Average pain</td><td>5.62</td><td>5.73</td><td>5.33</td></tr><tr><td>&#x02003;Range</td><td>3&#x02013;8</td><td>3&#x02013;8</td><td>3&#x02013;8</td></tr><tr><td>Average current pain</td><td>5.8</td><td>5.9</td><td>5.58</td></tr><tr><td>&#x02003;Range</td><td>0&#x02013;9</td><td>1&#x02013;8</td><td>0&#x02013;9</td></tr></tbody></table></table-wrap>
</p><sec id="Sec14"><title>Primary outcome</title><p id="Par33">According to analysis of the seven treatment sessions, the magnitude of pain score reduction tended to decrease in both treatment arm 1 and control arm, while it increased in treatment arm 2 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). For the among-group comparisons at each time point, there was a statistically significant improvement in the pain score in treatment arm 2 on the fifth day of treatment (Table <xref rid="Tab6" ref-type="table">6</xref>) (<italic>P</italic>&#x0003c;0.05). There was no difference among the three groups observed in a repeated measures design approach.<fig id="Fig2"><label>Fig. 2</label><caption><p>Changes of pain reduction scores in the three study arms. (Group 1: Treatment arm 1; Group 2: Control group; Group 3: Treatment Arm 2)</p></caption><graphic xlink:href="12906_2017_1838_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Changes of NRS reduction in the three study arms <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left(\overline{x}\pm SD\right) $$\end{document}</tex-math><mml:math id="M2" display="inline"><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#x02015;</mml:mo></mml:mover><mml:mo>&#x000b1;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12906_2017_1838_Article_IEq1.gif"/></alternatives></inline-formula>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Day 1</td><td>1.93&#x000a0;&#x000b1;&#x000a0;1.21</td><td>1.36&#x000a0;&#x000b1;&#x000a0;1.15</td><td>1.86&#x000a0;&#x000b1;&#x000a0;1.03</td><td>0.36</td></tr><tr><td>Day 2</td><td>1.93&#x000a0;&#x000b1;&#x000a0;1.14</td><td>1.14&#x000a0;&#x000b1;&#x000a0;0.77</td><td>1.57&#x000a0;&#x000b1;&#x000a0;1.28</td><td>0.17</td></tr><tr><td>Day 3</td><td>1.93&#x000a0;&#x000b1;&#x000a0;1.14</td><td>1.07&#x000a0;&#x000b1;&#x000a0;1.07</td><td>1.64&#x000a0;&#x000b1;&#x000a0;1.22</td><td>0.14</td></tr><tr><td>Day 4</td><td>1.43&#x000a0;&#x000b1;&#x000a0;1.16</td><td>1.21&#x000a0;&#x000b1;&#x000a0;0.97</td><td>1.43&#x000a0;&#x000b1;&#x000a0;1.02</td><td>0.83</td></tr><tr><td>Day 5</td><td>1.36&#x000a0;&#x000b1;&#x000a0;1.01</td><td>0.86&#x000a0;&#x000b1;&#x000a0;0.86</td><td>1.79&#x000a0;&#x000b1;&#x000a0;0.89<sup>a</sup>
</td><td>0.04</td></tr><tr><td>Day 6</td><td>1.29&#x000a0;&#x000b1;&#x000a0;1.14</td><td>0.93&#x000a0;&#x000b1;&#x000a0;0.83</td><td>1.79&#x000a0;&#x000b1;&#x000a0;1.19<sup>a</sup>
</td><td>0.11</td></tr><tr><td>Day 7</td><td>1.36&#x000a0;&#x000b1;&#x000a0;1.08</td><td>1.00&#x000a0;&#x000b1;&#x000a0;1.04</td><td>1.29&#x000a0;&#x000b1;&#x000a0;1.07</td><td>0.65</td></tr><tr><td>Main effect of time (<italic>P</italic>-value)*</td><td colspan="3">&#x0003e;0.05</td><td/></tr></tbody></table><table-wrap-foot><p>*There was no interaction between the changing trends in pain reduction scores and intervention factor of the three groups over time</p><p>
<sup>a</sup>Compared with the control group, the difference in cancer pain reduction scores was statistically significant, <italic>P</italic>&#x0003c;0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par34">On the other hand, for the patients&#x02019; perception of the overall improvement, the results of PGIC measurement across the three arms revealed that the difference in their PGIC scores was not statistically significant (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05) (Table <xref rid="Tab7" ref-type="table">7</xref>).<table-wrap id="Tab7"><label>Table 7</label><caption><p>PGIC scores in the three study arms <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left(\overline{x}\pm SD\right) $$\end{document}</tex-math><mml:math id="M4" display="inline"><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#x02015;</mml:mo></mml:mover><mml:mo>&#x000b1;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12906_2017_1838_Article_IEq2.gif"/></alternatives></inline-formula>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Day 7</td><td>2.42&#x000a0;&#x000b1;&#x000a0;0.79</td><td>2.64&#x000a0;&#x000b1;&#x000a0;0.67</td><td>2.56&#x000a0;&#x000b1;&#x000a0;0.53</td><td>0.74</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec15"><title>Secondary outcomes</title><p id="Par35">Both the Global Health Scale and the Functional Scale increased during the treatment course (Tables <xref rid="Tab8" ref-type="table">8</xref>, <xref rid="Tab9" ref-type="table">9</xref> and Fig. <xref rid="Fig3" ref-type="fig">3</xref>), whereas the Symptom Scale decreased (Table <xref rid="Tab10" ref-type="table">10</xref>). However, there was no statistically significant difference found across the three arms in all the EORTC QLQ-C30 domains (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05). Additionally, no difference between the three groups was observed in a repeated measures design approach.<table-wrap id="Tab8"><label>Table 8</label><caption><p>Global health score and changes in the three study arms <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left(\overline{x}\pm SD\right) $$\end{document}</tex-math><mml:math id="M6" display="inline"><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#x02015;</mml:mo></mml:mover><mml:mo>&#x000b1;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12906_2017_1838_Article_IEq3.gif"/></alternatives></inline-formula>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Baseline</td><td>39.88&#x000a0;&#x000b1;&#x000a0;19.39</td><td>32.74&#x000a0;&#x000b1;&#x000a0;18.90</td><td>35.12&#x000a0;&#x000b1;&#x000a0;15.04</td><td>0.57</td></tr><tr><td>Day 7</td><td>50.60&#x000a0;&#x000b1;&#x000a0;17.13</td><td>44.64&#x000a0;&#x000b1;&#x000a0;20.83</td><td>48.81&#x000a0;&#x000b1;&#x000a0;16.62</td><td>0.68</td></tr><tr><td>Follow up</td><td>50.60&#x000a0;&#x000b1;&#x000a0;19.47</td><td>45.24&#x000a0;&#x000b1;&#x000a0;16.89</td><td>46.43&#x000a0;&#x000b1;&#x000a0;18.98</td><td>0.73</td></tr><tr><td>Main effect of time (<italic>P</italic>-value)*</td><td colspan="3">&#x0003c;0.05</td><td/></tr></tbody></table><table-wrap-foot><p>*There was no interaction between the changing trends in Global Health scores and the three groups&#x02019; intervention factors over time</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab9"><label>Table 9</label><caption><p>Functional scale score and changes in the three study arms <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left(\overline{x}\pm SD\right) $$\end{document}</tex-math><mml:math id="M8" display="inline"><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#x02015;</mml:mo></mml:mover><mml:mo>&#x000b1;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12906_2017_1838_Article_IEq4.gif"/></alternatives></inline-formula>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Baseline</td><td>90.29&#x000a0;&#x000b1;&#x000a0;4.00#</td><td>87.24&#x000a0;&#x000b1;&#x000a0;3.89</td><td>88.60&#x000a0;&#x000b1;&#x000a0;3.56</td><td>0.12</td></tr><tr><td>Day 7</td><td>91.56&#x000a0;&#x000b1;&#x000a0;4.94</td><td>89.21&#x000a0;&#x000b1;&#x000a0;4.16</td><td>90.35&#x000a0;&#x000b1;&#x000a0;4.10</td><td>0.38</td></tr><tr><td>Follow up</td><td>90.79&#x000a0;&#x000b1;&#x000a0;4.85</td><td>89.78&#x000a0;&#x000b1;&#x000a0;3.53</td><td>90.48&#x000a0;&#x000b1;&#x000a0;4.27</td><td>0.81</td></tr><tr><td>Main effect of time<break/>(<italic>P</italic>-value)*</td><td colspan="3">&#x0003c;0.05</td><td/></tr></tbody></table><table-wrap-foot><p>*There was no interaction between the changing trends of Functional scale scores and the three groups&#x02019; intervention factors over time</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Global health scores and changes among the 3 groups. (Group 1: Treatment arm 1; Group 2: Control group; Group 3: Treatment Arm 2)</p></caption><graphic xlink:href="12906_2017_1838_Fig3_HTML" id="MO3"/></fig>
<table-wrap id="Tab10"><label>Table 10</label><caption><p>Symptom scale score and changes in the three study arms <inline-formula id="IEq5"><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left(\overline{x}{x}\pm SD\right) $$\end{document}</tex-math><mml:math id="M10" display="inline"><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#x02015;</mml:mo></mml:mover><mml:mo>&#x000b1;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12906_2017_1838_Article_IEq5.gif"/></alternatives></inline-formula>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Baseline</td><td>4.46&#x000a0;&#x000b1;&#x000a0;1.59</td><td>5.45&#x000a0;&#x000b1;&#x000a0;1.88</td><td>5.21&#x000a0;&#x000b1;&#x000a0;1.86</td><td>0.32</td></tr><tr><td>Day 7</td><td>3.36&#x000a0;&#x000b1;&#x000a0;2.39</td><td>3.93&#x000a0;&#x000b1;&#x000a0;1.90</td><td>4.17&#x000a0;&#x000b1;&#x000a0;1.92</td><td>0.57</td></tr><tr><td>Follow up</td><td>3.72&#x000a0;&#x000b1;&#x000a0;2.02</td><td>3.91&#x000a0;&#x000b1;&#x000a0;1.78</td><td>4.27&#x000a0;&#x000b1;&#x000a0;2.10</td><td>0.28</td></tr><tr><td>Main effect of time<break/>(<italic>P</italic>-value)*</td><td colspan="3">&#x0003c;0.05</td><td/></tr></tbody></table><table-wrap-foot><p>*There was no interaction between the changing trends of Symptom scale scores and the three groups&#x02019; intervention factors over time</p></table-wrap-foot></table-wrap>
</p><p id="Par36">The KPS score of the three arms showed an increasing trend during the treatment course, but the difference across the three arms was not statistically significant (<italic>P</italic>&#x0003e;0.05) (Table <xref rid="Tab11" ref-type="table">11</xref> and Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<table-wrap id="Tab11"><label>Table 11</label><caption><p>KPS score and changes in the three study arms <inline-formula id="IEq6"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ \left(\overline{x}\pm SD\right) $$\end{document}</tex-math><mml:math id="M12" display="inline"><mml:mfenced close=")" open="("><mml:mrow><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo stretchy="true">&#x02015;</mml:mo></mml:mover><mml:mo>&#x000b1;</mml:mo><mml:mi mathvariant="italic">SD</mml:mi></mml:mrow></mml:mfenced></mml:math><inline-graphic xlink:href="12906_2017_1838_Article_IEq6.gif"/></alternatives></inline-formula>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time</th><th>Arm 1<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Control arm<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>Arm 2<break/>(<italic>n</italic>&#x000a0;=&#x000a0;14)</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Day 1</td><td>70.00&#x000a0;&#x000b1;&#x000a0;15.19</td><td>72.86&#x000a0;&#x000b1;&#x000a0;13.83</td><td>67.14&#x000a0;&#x000b1;&#x000a0;9.14</td><td>0.51</td></tr><tr><td>Day 2</td><td>70.00&#x000a0;&#x000b1;&#x000a0;15.19</td><td>72.86&#x000a0;&#x000b1;&#x000a0;13.83</td><td>67.14&#x000a0;&#x000b1;&#x000a0;9.14</td><td>0.51</td></tr><tr><td>Day 3</td><td>70.00&#x000a0;&#x000b1;&#x000a0;15.19</td><td>73.57&#x000a0;&#x000b1;&#x000a0;13.36</td><td>67.86&#x000a0;&#x000b1;&#x000a0;9.75</td><td>0.51</td></tr><tr><td>Day 4</td><td>70.00&#x000a0;&#x000b1;&#x000a0;15.19</td><td>73.57&#x000a0;&#x000b1;&#x000a0;13.36</td><td>68.57&#x000a0;&#x000b1;&#x000a0;9.49</td><td>0.57</td></tr><tr><td>Day 5</td><td>70.71&#x000a0;&#x000b1;&#x000a0;14.92</td><td>73.57&#x000a0;&#x000b1;&#x000a0;13.36</td><td>68.57&#x000a0;&#x000b1;&#x000a0;9.49</td><td>0.59</td></tr><tr><td>Day 6</td><td>70.71&#x000a0;&#x000b1;&#x000a0;14.92</td><td>73.57&#x000a0;&#x000b1;&#x000a0;13.36</td><td>68.57&#x000a0;&#x000b1;&#x000a0;9.49</td><td>0.59</td></tr><tr><td>Day 7</td><td>70.71&#x000a0;&#x000b1;&#x000a0;14.92</td><td>73.57&#x000a0;&#x000b1;&#x000a0;13.36</td><td>68.57&#x000a0;&#x000b1;&#x000a0;9.49</td><td>0.59</td></tr><tr><td>Main effect of time<break/>(<italic>P</italic>-value)*</td><td colspan="3">&#x0003c;0.05</td><td/></tr></tbody></table><table-wrap-foot><p>*There was no interaction between the changing trends of the KPS scores and the three groups&#x02019; intervention factors over time</p></table-wrap-foot></table-wrap>
<fig id="Fig4"><label>Fig. 4</label><caption><p>KPS score and changes among the 3 groups. (Group 1: Treatment arm 1; Group 2: Control group; Group 3: Treatment Arm 2)</p></caption><graphic xlink:href="12906_2017_1838_Fig4_HTML" id="MO4"/></fig>
</p></sec><sec id="Sec16"><title>Safety analysis</title><p id="Par37">The safety of acupuncture, including acupuncture related fainting, hematoma, curved and broken needles was also examined in the pilot study. Throughout the study period, no serious acupuncture-related adverse events occurred. There was only one reported episode of mild local bruising, at one acupuncture site, which was successfully managed with direct digital pressure administered by the practitioner.</p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par38">Acupuncture may be useful in controlling the pain experienced by many cancer patients. It is a complementary and conservative therapy that balances the flow of vital energy, and in turn helps to relieve pain. It is an analgesic adjunctive method for cancer patients that is worthy of additional high quality studies [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par39">Because of the small sample size, this pilot study mainly intends to examine the preliminary effects of the acupuncture protocol using the <italic>si guan xue</italic> for cancer pain management for a larger study and its safety. The primary outcomes were the trend of acupuncture in relieving cancer pain and patients&#x02019; subjective improvement as measured by the PGIC. Secondary outcomes were patients&#x02019; well-being as determined by the EORTC QLQ-C30 and the KPS. According to the data analysis, the effect of pain relief tended to decrease in treatment arm 1 (<italic>si guan xue</italic> only) and the control arm (commonly used acupoints only). However, it increased in treatment arm 2 (a combination of <italic>si guan xue</italic> and commonly used acupoints), especially on the fifth day of treatment. This phenomenon reflects the fact that acupuncture treatment takes time to accumulate and exert its analgesic effect, which is consistent with the clinical experience of our routine practice [<xref ref-type="bibr" rid="CR40">40</xref>]. On the other hand, although the trend of analgesic effect was still observed on days 6 and 7, it was not statistically significant. This may be due to the sample size of the pilot study, which is too small to detect any sustained effect.</p><p id="Par40">Also, it revealed that either the acupuncture at <italic>si guan xue</italic> or commonly used acupoints are effective in reducing cancer pain, but that the combination of these two appears to further enhance pain reduction. Thus, this seemed to be a better acupuncture protocol for cancer pain management. There are several possible explanations for this enhanced effect. Firstly, a special technique of acupuncture was used in treatment arm 2. The <italic>si guan xue</italic> was opened first before regulating the commonly used acupoints. It had been recognized that this technique could produce a stronger clinical effect [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Secondly, previous studies had suggested that acupuncture at the <italic>si guan xue</italic> could activate the <italic>qi</italic>, replenish the vital substances of the body and strengthen the visceral organs [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Thirdly, several other studies have also supported the claim that acupuncture at the <italic>si guan xue</italic> could give rise to sedative, antispasmodic and analgesic effects. Thus, the use of the <italic>si guan xue</italic> would be more effective in controlling cancer pain [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Though it was limited to patients with liver cancer, there has been one randomized controlled study of acupuncture at the <italic>si guan xue</italic>. It enrolled 86 patients and revealed that acupuncture achieved a better control on cancer pain than codeine treatment [<xref ref-type="bibr" rid="CR45">45</xref>]. The results of our pilot study are not only consistent with these previous findings, but also reveal that the beneficial effect on cancer pain is applicable to other cancer-related diseases.</p><p id="Par41">There was no statistically significant difference found across the three arms in the PGIC, EORTC QLQ-C30, and KPS scores (<italic>P</italic>&#x0003e;0.05). A possible explanation is that the treatment and evaluation period was too short to reveal the full effect of the acupuncture. However, these clinical outcomes might require longer observation times to see improvement, as documented by these scores. Therefore, the clinicians should contemplate the appropriate duration of acupuncture treatment for cancer pain. A course of 14 acupuncture sessions, or at least 2&#x000a0;weeks of treatment is needed for better management of this problem [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. In addition, the small sample size is another possible factor accounting for the negative results in the above outcomes.</p><sec id="Sec18"><title>Limitations of the pilot study</title><p id="Par42">As mentioned above, the main limitation of this study was the small sample size, which was inadequate to confirm the efficacy of acupuncture in the management of cancer pain. Moreover, the treatment and observation time were too short to reveal the full effect of the acupuncture. Seven patients even requested to continue their acupuncture treatment upon completion of the study. This may reflect the fact that acupuncture at the <italic>si guan xue</italic> helps to control their cancer pain and improve their quality of life, but a longer treatment course remains more desirable.</p></sec></sec><sec id="Sec19"><title>Conclusion</title><p id="Par43">The results of this pilot study indicate that acupuncture at the <italic>si guan xue</italic> plus commonly used acupoints tends to be effective in reducing cancer pain. It may also be beneficial in controlling cancer pain in advanced cancer patients. The use and addition of the <italic>si guan xue</italic> in acupuncture for cancer pain has also been found to be feasible and manageable. Although no firm conclusions can be drawn from such an under-powered study, it did show a trend towards an improvement in cancer pain scores. Therefore, further large scale and multi-centre randomized controlled trials of the <italic>si guan xue</italic> plus commonly used acupoints are warranted to confirm its treatment efficacy.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ANOVA</term><def><p id="Par6">Analysis of variance</p></def></def-item><def-item><term>EORTC QLQ-C30</term><def><p id="Par7">European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30</p></def></def-item><def-item><term>KPS</term><def><p id="Par8">Karnofsky&#x02019;s Performance Status</p></def></def-item><def-item><term>NRS</term><def><p id="Par9">Numeric rating scale</p></def></def-item><def-item><term>PGIC</term><def><p id="Par10">Patient global impression of change</p></def></def-item><def-item><term>STRICTA</term><def><p id="Par11">Standards for reporting interventions in clinical trials of acupuncture</p></def></def-item><def-item><term>WHO</term><def><p id="Par12">World health organization</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p id="Par44">There is no external funding for this study. The authors have no financial relationships to disclose.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par45">The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p id="Par46">TYL and LZL designed and led the entire study. TYL and LML analyzed and interpreted the patient data for generating the study results. TYL and WML drafted the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p id="Par47">The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par48">The consent form for the study participants was incorporated into the study protocol, and was approved by the Ethics Committee of Hong Kong East Cluster. Study consent, including that for data publication, was obtained from each participant prior to joining the study.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par49">The study protocol was approved by the Ethics Committee of Hong Kong East Cluster (Reference no.: HKEC-2012-024) before the start of this study. The informed consent to participate in our study was obtained from all participants prior to their involvement.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par50">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Is the number of cancer patients in the world increasing or decreasing? <ext-link ext-link-type="uri" xlink:href="http://www.who.int/features/cancer/zh/">http://www.who.int/features/cancer/zh/</ext-link>. Accessed 15 July 2013.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Browman</surname><given-names>GP</given-names></name></person-group><article-title>The WHO analgesic ladder for cancer pain management:stepping up the quality of its evaluation</article-title><source>The Journal of the American Medical Association</source><year>1995</year><volume>274</volume><issue>23</issue><fpage>1870</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1001/jama.1995.03530230056031</pub-id><pub-id pub-id-type="pmid">7500538</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherny</surname><given-names>NI</given-names></name></person-group><article-title>The Management of Cancer Pain</article-title><source>CA-A Cancer Journal for Clinicians</source><year>2000</year><volume>50</volume><issue>2</issue><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.3322/canjclin.50.2.70</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnstone</surname><given-names>PAS</given-names></name><name><surname>Polston</surname><given-names>GR</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name></person-group><article-title>Integration of acupuncture into the oncology clinic</article-title><source>Palliat Med</source><year>2002</year><volume>16</volume><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1191/0269216302pm540oa</pub-id><pub-id pub-id-type="pmid">12047000</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Longxiang</surname><given-names>H</given-names></name><name><surname>Jizhou</surname><given-names>Y</given-names></name></person-group><article-title>The culmination of Acupuncture</article-title><source>Beijing: People's Medical Publishing House</source><year>2010</year><volume>7</volume><fpage>47</fpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>T</given-names></name></person-group><article-title>Meta clinical experience of si guan xue</article-title><source>Journal of Inner Mongolia Traditional Chinese Medicine</source><year>2007</year><volume>9</volume><fpage>49</fpage><lpage>51</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Clinical application of si guan xue</article-title><source>Journal of Jilin Traditional Chinese Medicine</source><year>2005</year><volume>25</volume><issue>4</issue><fpage>34</fpage></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010,3;7(3):e1000251.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Hongwen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Investigation of cancer pain treatment in 43 cases [J]</article-title><source>Pharmaceutical Care and Research</source><year>2004</year><volume>4</volume><issue>3</issue><fpage>287</fpage><lpage>288</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Jun</surname><given-names>P</given-names></name></person-group><article-title>Clinical observation on the efficacy of Integrative treatment of bone metastases pain in 23 cases [J]</article-title><source>Journal of Yunnan Chinese medicine</source><year>2008</year><volume>29</volume><issue>10</issue><fpage>12</fpage><lpage>13</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y-h</given-names></name></person-group><article-title>Chinese medicine combined with chemotherapy in the treatment of advanced breast cancer bone metastasis pain in 53 cases [J]</article-title><source>Journal of Henan Traditional Chinese Medicine</source><year>2000</year><volume>15</volume><issue>5</issue><fpage>53</fpage><lpage>54</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Danhong</surname><given-names>W</given-names></name></person-group><article-title>Integrative medicine metastatic bone pain in 30 cases [J]</article-title><source>Journal of Fujian Traditional Chinese Medicine</source><year>2001</year><volume>32</volume><issue>5</issue><fpage>12</fpage></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Clinical observation on the efficacy of Integrative treatment of bone metastases pain in 27 cases [J]</article-title><source>Journal of Henan Medical College</source><year>2010</year><volume>22</volume><issue>5</issue><fpage>575</fpage><lpage>577</lpage></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Urbaniak GC,Plous S. Research Randomizer (Version 4.0) [Computer software]. <ext-link ext-link-type="uri" xlink:href="http://www.randomizer.org//form.htm">http://www.randomizer.org//form.htm</ext-link>. Accessed 22 December 2011.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacPherson</surname><given-names>H</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Hammerschlag</surname><given-names>R</given-names></name><etal/></person-group><article-title>Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><issue>6</issue><pub-id pub-id-type="doi">10.1371/journal.pmed.1000261</pub-id><pub-id pub-id-type="pmid">20543992</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Liu Z, Liang L. Essentials of Chinese medicine volume 1. New York : Springer-Verlag London Limited. 2009:284&#x02013;8.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wenbin</surname><given-names>F</given-names></name></person-group><article-title>Pain caused by healthy qi deficiency and its management with moxibustion</article-title><source>Hong Kong : Proceedings of the International Academic Seminar of Acumoxa in Pain Management</source><year>2009</year><volume>5</volume><fpage>355</fpage><lpage>358</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Acupuncture treatment of cancer pain in 160 cases</article-title><source>Emergency of Chinese Medicine of China</source><year>2008</year><volume>17</volume><issue>4</issue><fpage>543</fpage><lpage>544</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Xiaohuang</surname><given-names>XBQR</given-names></name><etal/></person-group><article-title>Clinical observation on the efficacy of combination of acupuncture and topical treatment of cancer pain</article-title><source>Practical Journal of Chinese Medicine</source><year>1998</year><volume>11</volume><fpage>7</fpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jinhua</surname><given-names>X</given-names></name></person-group><article-title>The combination of electroacupuncture with the three-step analgesia for the treatment of cancer pain in 15 cases</article-title><source>Shanghai Journal of Acupuncture</source><year>1999</year><volume>18</volume><issue>5</issue><fpage>21</fpage></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Guiping Chen, Jinhong Yang, Mei Juan Yu, et al. Acupuncture treatment of radiotherapy and chemotherapy gastrointestinal reactions in 44 cases. Chinese acupuncture and moxibustion, 1996,16(7):9.</mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Rong Mu, Qu Bin Zheng, Wei Zhu Yang, et al. Observation on therapeutic effect of acupuncture of Neiguan in complications of interventional treatment on hepatic carcinoma. Chinese Journal of Integrated Chinese and Western Medicine, 1995,16(10):611.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Observation on acupuncture analgesic effect of cancer pain</article-title><source>Practical Journal of Chinese Medicine</source><year>1999</year><volume>15</volume><issue>7</issue><fpage>28</fpage></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name></person-group><article-title>Acupuncture treatment of hepatocellular carcinoma after interventional chemotherapy induced hiccups</article-title><source>Shanxi Chinese Medicine</source><year>1997</year><volume>13</volume><issue>2</issue><fpage>42</fpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D</given-names></name></person-group><article-title>The clinical study of acupuncture of analgesic effect on cancer pain</article-title><source>Chinese acupuncture and moxibustion</source><year>1998</year><volume>1</volume><issue>18</issue><fpage>17</fpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bian</surname><given-names>R</given-names></name></person-group><article-title>The clinical study of acupuncture treatment on cancer pain of stomach cancer</article-title><source>Journal of Chinese Medicine</source><year>1995</year><volume>36</volume><issue>5</issue><fpage>277</fpage><lpage>280</lpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>He</surname><given-names>K</given-names></name></person-group><article-title>Research status and prospects of acupuncture and moxibustion regulating immunological function</article-title><source>Shanghai Journal of Acupuncture and moxibustion</source><year>1999</year><volume>18</volume><issue>1</issue><fpage>46</fpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Clinical and experimental research survey of acupuncture and moxibustion on antitumor effect</article-title><source>Hubei Journal of Chinese Medicine</source><year>1998</year><volume>5</volume><fpage>59</fpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name></person-group><article-title>Observation on the therapeutic effect and nursing care of acupuncture combined with three step analgesic ladder treatment of cancer pain</article-title><source>Modern Nursing</source><year>2002</year><volume>8</volume><issue>8</issue><fpage>588</fpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>YL</given-names></name><name><surname>Yu</surname><given-names>LR</given-names></name></person-group><article-title>Observation on therapeutic effect of needle-retaining method of triple acupuncture in 80 cases of pain due to liver cancer</article-title><source>Chin Acupuc Moxibustion</source><year>2000</year><volume>21</volume><fpage>211</fpage><lpage>212</lpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Schmidt</surname><given-names>K</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Acupuncture for the relief of cancer-related pain:a systematic review</article-title><source>Eur J Pain</source><year>2005</year><volume>9</volume><fpage>437</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.ejpain.2004.10.004</pub-id><pub-id pub-id-type="pmid">15979024</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>FD</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy of acupuncture in treatment of cancer pain: a systematic review</article-title><source>Chinese Journal of Integrative Medicine</source><year>2010</year><volume>8</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.3736/jcim20100601</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">National Institutes of Health: Warren Grant Magnuson Clinical Center. Pain Intensity Instruments. <ext-link ext-link-type="uri" xlink:href="http://www.mvltca.net/Presentations/mvltca.pdf">http://www.mvltca.net/Presentations/mvltca.pdf</ext-link>, Accessed 01 December 2011.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>JT</given-names></name><name><surname>Young</surname><given-names>JP</given-names><suffix>Jr</suffix></name><name><surname>LaMoreaux</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale</article-title><source>Pain</source><year>2001</year><volume>94</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S0304-3959(01)00349-9</pub-id><pub-id pub-id-type="pmid">11690728</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">EORTC Quality of Life Department. The Chinese version of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30). <ext-link ext-link-type="uri" xlink:href="http://www.eortc.be/home/qol/files/C30/QLQ-C30%20Chinese%20Mandarin%20Simplified.pdf">http://www.eortc.be/home/qol/files/C30/QLQ-C30%20Chinese%20Mandarin%20Simplified.pdf</ext-link>. Accessed 07 Jan 2012.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed). Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949:196.</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aung</surname><given-names>S</given-names></name></person-group><article-title>The clinical use of acupuncture in oncology : symptom control</article-title><source>Acupunct Med</source><year>1994</year><volume>12</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1136/aim.12.1.37</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Hyangsook Lee, Katja Schmidt, Edzard Ernst. Acupuncture for the relief of cancer-related pain &#x02013; a systematic review. European Journal of Pain. 2005;9(4):437&#x02013;444.</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnstone</surname><given-names>PA</given-names></name><name><surname>Polston</surname><given-names>GR</given-names></name><name><surname>Niemtzow</surname><given-names>RC</given-names></name><name><surname>Martin</surname><given-names>PJ</given-names></name></person-group><article-title>Integration of acupuncture into the oncology clinic</article-title><source>Palliat Med</source><year>2002</year><volume>16</volume><issue>3</issue><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1191/0269216302pm540oa</pub-id><pub-id pub-id-type="pmid">12047000</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name></person-group><article-title>Acupuncture for the treatment of cancer pain: a systematic review of randomized clinical trials</article-title><source>Support Care Cancer</source><year>2012</year><volume>20</volume><fpage>1147</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1007/s00520-012-1432-9</pub-id><pub-id pub-id-type="pmid">22447366</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>X</given-names></name></person-group><article-title>Experience on clinical application &#x0201c;si guan xue&#x0201d;</article-title><source>Practical Journal of Chinese Medicine</source><year>2006</year><volume>22</volume><issue>5</issue><fpage>300</fpage></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>YJ</given-names></name></person-group><article-title>Preliminary knowledge on opening of si guan xue</article-title><source>Chinese Medicine of Shanxi</source><year>2008</year><volume>29</volume><issue>8</issue><fpage>1103</fpage><lpage>1104</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>T</given-names></name></person-group><article-title>Meta clinical experience on si guan xue</article-title><source>Inner Mongolia Traditional Chinese Medicine</source><year>2007</year><volume>9</volume><fpage>49</fpage><lpage>51</lpage></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><article-title>Clinical application of si guan xue</article-title><source>J Med</source><year>2005</year><volume>25</volume><issue>4</issue><fpage>34</fpage></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>QH</given-names></name></person-group><article-title>Analgesic efficacy and mechanism of wrist-ankle acupuncture on pain caused by liver cancer</article-title><source>Chinese Journal of Integrative Medicine</source><year>2005</year><volume>15</volume><fpage>131</fpage><lpage>133</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Follwell</surname><given-names>M</given-names></name><name><surname>Burman</surname><given-names>D</given-names></name><name><surname>Le</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Phase II study of an outpatient palliative care intervention in patients with metastatic cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>2</issue><fpage>206</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.17.7568</pub-id><pub-id pub-id-type="pmid">19064979</pub-id></element-citation></ref></ref-list></back></article>